

## **MONTELUKAST/ZAFIRLUKAST** SPECIAL AUTHORIZATION REQUEST FORM

Please complete all required sections to allow your request to be processed.

Patients may or may not meet eligibility requirements as established by

PATIENT INFORMATION	•						RAGE TYPE:	
PATIENT INFORMATION  PATIENT LAST NAME	FIRST NAME	EIDST NAME INITIAL						
I ATILIVI LAGI IVAIVIE	I INST INAIVIE						perta Blue Cross	
DATE OF BIRTH: Year / Month / Day	ALDEDTA DEDCONAL HI					<del>-</del>	perta Human Services	
DATE OF BIRTH. Teal / WOHLH / Day	ALDER I A PERSONAL FI	ALBERTA PERSONAL HEALTH NUMBER					ner	
		1						
STREET ADDRESS	CITY	PR	OV	POS	TAL CODE	IDENT	TIFICATION/CLIENT/COVERAGE No:	
PRESCRIBER INFORMATION								
PRESCRIBER LAST NAME FIRST NAME INITIAL				PRESCRIBER PROFESSIONAL ASSOCIATION REGISTRATION				
				☐ CPSA ☐ ACO REGISTRATION NO.				
				☐ CARNA ☐ ADA+C				
STREET ADDRESS				ACP Other				
				PHONE: FAX:				
CITY, PROVINCE								
POSTAL CODE EAY NI IMBED I						/IIIQT D	DE DDOVIDED WITH EACH	
				FAX NUMBER MUST BE PROVIDED WITH EACH REQUEST SUBMITTED				
Indicate which drug is requested (c	heck one box):	Мс	onteluka	ast (	5mg + 10m	ng) L	Zafirlukast (20mg)	
Criteria for Coverage of MONTELUKAS	T / ZAFIRLUKAST							
For the prophylaxis and chronic treatme	ent of asthma in patient	s ov	er the a	ige o	f 18 who m	eet one	of the following criteria:	
a) when used as adjunctive therapy in p				_			•	
long-acting beta 2 agonists. Patients m		g-a	cting be	eta 2	agonists or	have d	lemonstrated persistent	
symptoms while on long-acting beta 2 agonists, OR								
b) cannot operate inhaler devices.								
For the prophylaxis of exercise-induced bronchoconstriction in patients over the age of 18 where tachyphylaxis exists for long-								
acting beta 2 agonists.								
Special authorization for both criteria may be granted for 6 months. This product is eligible for auto-renewal.								
Note: Refer to the Alberta Drug Benefit List for Restricted Benefit coverage of patients 2 to 18 years of age inclusive for Montelukast and 12 to 18 years of								
age inclusive for Zafirlukast.								
■ NEW Please provide the following information for NEW requests (Section 1, AND Section 2 or 3 must be completed):								
Section 1: Indication:								
Prophylaxis and chronic treatment of asthma (If yes, proceed to Section 2A or 2B only).								
☐ Prophylaxis of exercise-induced bronchoconstriction (If yes, proceed to Section 3 only).								
Other (specify):								
Section 2: Prophylaxis and chronic treatment of asthma:								
A. Previous Medication Use:	unent of astima.					Р	Use of Inhaler Device	
a) Please indicate if an inhaled glucocorticosteroid was used:								
Yes No (If no, specify reason):_						Please indicate if the patient has difficulty using an inhaler device:		
						l		
b) Please indicate if a long-acting beta 2 agonist (e.g. salmeterol or formoterol) was tried:							Yes (Please elaborate on the ture of the difficulty)	
☐ Yes → Response: ☐ Persistent symptoms							ture of the difficulty)	
Other (specify)							l No	
☐ No (If no, specify reason):						⊔	No	
Section 3: Prophylaxis of exercise indu				_	_			
Does this patient have tachyphylaxis with long-acting beta 2 agonists?   Yes   No  Other (specify):								
Additional information relating to request:								
RENEWAL: This product is eligible for auto-renewal. A Special Authorization renewal request is required only if the Special Authorization approval has								
lapsed (i.e. the patient has <u>not</u> made a claim for the drug product during the Approval Period).								
Please indicate response to therapy:								
PRESCRIBER'S SIGNATURE			ard this r					
<ul> <li>Alberta Blue Cross, Clinical Drug Services</li> <li>10009-108 Street NW, Edmonton, Alberta T5J 3C5</li> </ul>								
							28-4106 toll free all other areas	
ONCE YOUR REQUEST HAS SUCCESSFULLY TRANSMITTED, PLEASE DO NOT MAIL OR RE-FAX YOUR REQUEST.								